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Abstract
Background and Objectives Caspofungin is an
echinocandin antifungal agent used as first-line therapy for
the treatment of invasive candidiasis. The maintenance
dose is adapted to body weight (BW) or liver function
(Child-Pugh score B or C). We aimed to study the phar-
macokinetics of caspofungin and assess pharmacokinetic
target attainment for various dosing strategies.
Methods Caspofungin pharmacokinetic data from 21
intensive care unit (ICU) patients was available. A popu-
lation pharmacokinetic model was developed. Various
dosing regimens (loading dose/maintenance dose) were
simulated: licensed regimens (I) 70/50 mg (for BW
\80 kg) or 70/70 mg (for BW[80 kg); and (II) 70/35 mg
(for Child-Pugh score B); and adapted regimens (III)
100/50 mg (for Child-Pugh score B); (IV) 100/70 mg; and
(V) 100/100 mg. Target attainment based on a preclinical
pharmacokinetic target for Candida albicans was assessed
for relevant minimal inhibitory concentrations (MICs).
Results A two-compartment model best fitted the data.
Clearance was 0.55 L/h and the apparent volumes of
distribution in the central and peripheral compartments
were 8.9 and 5.0 L, respectively. The median area under
the plasma concentration–time curve from time zero to
24 h on day 14 for regimens I–V were 105, 65, 93, 130,
and 186 mgh/L, respectively. Pharmacokinetic target
attainment was 100 % (MIC 0.03 lg/mL) irrespective of
dosing regimen but decreased to (I) 47 %, (II) 14 %, (III)
36 %, (IV) 69 %, and (V) 94 % for MIC 0.125 lg/mL.
Conclusion The caspofungin maintenance dose should not
be reduced in non-cirrhotic ICU patients based on the Child-
Pugh score if this classification is driven by hypoalbu-
minemia as it results in significantly lower exposure. A
higher maintenance dose of 70 mg in ICU patients results in
target attainment of[90 % of the ICU patients with species
with an MIC of up to 0.125 lg/mL.
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Key Points
A population pharmacokinetic model of caspofungin
in critically ill patients greatly assisted in applying
simulations to derive pharmacokinetic target
attainment.
The caspofungin dose should not be reduced in non-
cirrhotic intensive care unit (ICU) patients classified
as Child-Pugh B or C if this classification is driven
by hypoalbuminemia.
A higher maintenance dose of caspofungin 70 mg in
ICU patients results in target attainment of[90 % of
the ICU patients with species with a minimal
inhibitory concentration of up to 0.125 lg/mL.
1 Introduction
Critically ill patients are at increased risk for infections and
about 20 % of infections in intensive care unit (ICU)
patients are caused by fungal infections such as by Candida
or Aspergillus spp. [1]. Caspofungin is an echinocandin
antifungal agent licensed as a first-line therapy for invasive
candidiasis in patients with moderate to severe illness and/
or recent exposure to azoles [2]. The efficacy of
echinocandin therapy for the treatment of invasive can-
didiasis is higher than with other antifungal agents. An
adequate response to echinocandins is generally achieved
in 66–90 % of patients [3, 4]. Echinocandins work by
inhibiting the synthesis of b-(1,3)-D-glucan, an important
component of the fungal cell wall.
Caspofungin is administered intravenously and the
dosage is based on body weight (BW). The clinical
guideline of the International Infectious Disease Society
recommends a loading dose of 70 mg and subsequent daily
maintenance doses of 50 mg [2]. In addition, the mainte-
nance dose is recommended to be increased to 70 mg for
patients with BW[80 kg and decreased to 35 mg for
patients with moderate or severe hepatic impairment,
classified as Child-Pugh B or C [5, 6]. The Child-Pugh
score is a marker for severity of liver function impairment
that is composed of several markers of liver function such
as albumin serum values and the presence of ascites [7].
Recently, we analyzed the pharmacokinetics of caspo-
fungin in 21 ICU patients using a non-compartmental
approach [8]. Total caspofungin exposure (area under the
plasma concentration–time curve [AUC] from time zero to
24 h [AUC24]) did not seem to be altered in this population
as compared with other populations, even though dose
reductions would have been indicated in most patients
based on their Child-Pugh scores [8]. It should be noted
that Child-Pugh scoring was developed in patients with
cirrhosis and not in ICU patients. Large inter-individual
variability (IIV) in caspofungin exposures was observed
among ICU patients [8].
Next to pharmacokinetic considerations, pharmacody-
namic factors should be taken into account to identify the
best dose strategy for caspofungin in ICU patients. Various
studies have shown that AUC/minimal inhibitory concen-
tration (MIC) best described the pharmacokinetic–phar-
macodynamic relationship for caspofungin, micafungin,
and anidulafungin [9–11]. Murine infection models of
caspofungin explored the target AUC/MIC ratio associated
with efficacy [9, 11]. An AUC/MIC ratio of 865 was
associated with a 1-log kill/24 h in a neutropenic mouse
model of disseminated Candida albicans [11, 12]. To date,
a caspofungin pharmacokinetic–pharmacodynamic target
in humans has not yet been established.
The current study analyzed the pharmacokinetics of
caspofungin in ICU patients using non-linear mixed–ef-
fects modelling to obtain a better mechanistic under-
standing of the pharmacokinetic properties of the drug and
to be able to characterize potential covariate relationships
with higher statistical power. We were specifically inter-
ested in the effects of BW and Child-Pugh scores on
exposures, as the current dosing of caspofungin is adapted
based on these parameters. In addition, non-linear mixed–
effects modelling allows simulations of different dosing
regimens with corresponding exposures and assessment of
target attainment for these regimens.
2 Methods
2.1 Study Design, Drug Regimen, and Population
The study was approved by the local ethics committee
(Commissie Mensgebonden Onderzoek regio Arnhem-Ni-
jmegen number 2011/346, ClinicalTrials.gov identifier
NCT01533558 [38]) and informed consent was given by all
participants. Inclusion criteria included admission to the
ICU, caspofungin therapy for suspected or proven infection
or for prophylaxis, age[18 years when starting caspo-
fungin, started therapy a maximum of 2 days before
inclusion, and management with a central venous catheter.
Exclusion criteria included allergy for echinocandins or
excipients, known HIV, hepatitis B or C infection, or a
history of drug or alcohol abuse.
Dosing was as prescribed by the physician in atten-
dance: a 70 mg loading dose on day 1 followed by either
50 mg maintenance daily for patients weighing B80 kg or
a 70 mg maintenance for patients with BW[80 kg. The
maintenance dose should be reduced to 35 mg for patients
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classified as Child-Pugh B or C. Caspofungin was admin-
istered intravenously over approximately 1 h. Patients were
treated as long as clinically relevant but the duration of the
study (i.e., sampling of patients) was limited to 14 days of
caspofungin treatment. If patients stopped treatment before
14 days, pharmacokinetic washout samples until 3 days
after cessation of therapy were taken.
Patient demographics were collected and included sex,
age, race, weight, body mass index (BMI), lean body mass
(LBM [13]), indication for ICU admission, indication for
caspofungin, clinical characteristics, chemistry, and
hematological parameters. In addition, the APACHE II
score (Acute Physiology and Chronic Health Evaluation II;
severity of disease classification) within 24 h of ICU
admission, SOFA score (Sequential Organ Failure
Assessment score, to assess patients during their stay at an
ICU) and Child–Pugh class, co-medication, and (type of)
renal replacement therapy were recorded.
2.2 Pharmacokinetic Sampling and Analysis
Patients were intensively sampled (2 mL) on days 3 (±1)
and 7 (±1) of therapy at t = 0 (pre-dose) and 0.5, 1, 2, 4, 6,
8, 12, 16, 20, and 24 h post-dose, and additional trough
samples (pre-dose) were taken on other study days. Details
on the sample preparation and the assay (validated ultra-
performance liquid chromatography–fluorescence method)
have been described previously [8].
2.3 Pharmacokinetic Model
One-, two-, and three-compartment models were consid-
ered based on a review of the literature and on visual
inspection of the data. IIV was estimated using an expo-
nential model. The primary pharmacokinetic parameters
were clearance (CL) and volume of distribution (Vd).
Proportional, additive, and combined additive and propor-
tional models were evaluated for residual variability. Both
a single covariance matrix on the first compartment and
multiple omega blocks for the individual compartments as
a full covariance matrix on all compartments were con-
sidered for the inter-individual random effects.
Model selectionwas initially based on the objective function
value (OFV) computed as –2 log likelihood, where a decrease
inOFV of C3.84was considered significant (Chi-squared [v2],
1 degree of freedom [df], p\0.05). In addition, standard
goodness-of-fit (GOF) plots, including the observed versus the
population- and individual-predicted concentrations, and con-
ditional weighted residuals versus time after dose and popula-
tion-predicted concentration were used for model evaluation.
Also, the precision of the parameter estimates, eta-shrinkage,
and IIV was assessed. Good candidate models were further
evaluated by a visual predictive check (VPC).
After selection of the base model, various covariates were
tested on CL and Vd by a stepwise covariate model (scm) as
implemented in Perl-speaks-NONMEM (PsN 4.2.0), using
forward selectionandbackwardelimination [14].Onlybaseline
values were considered. Continuous covariates included age,
BW, length, LBM, BMI, body temperature, serum creatinine,
ureum, albumin, liver enzymes (alanine aminotransferase,
aspartate aminotransferase, c-glutamyl transpeptidase, alkaline
phosphatase, bilirubin), C-reactive protein, blood pH, and
glomerular filtration rate (GFR). Categorical covariates inclu-
ded sex, Child-Pugh score, and abnormal/normal GFR
(breakpoint[60 mL/min). All covariates were tested on both
CL and apparent volume of the central compartment (V1).
Linear, exponential, and power conditions were tested for
continuous covariates and linear conditions on categorical data,
all using a forward inclusion criterion of p\0.05 (OFV
decrease of C3.84, v2, 1 df) and a backward exclusion criterion
of p\0.01 (OFV increase of C6.64, v2, 1 df).
Based on physiological plausibility and extensive pre-
vious evidence, BW was incorporated a priori as a
covariate, both on CL (allometrically with a power expo-
nent of 0.75) and on Vd (power exponent of 1) and was
standardized to a typical 70 kg patient [15–18].
To assess the predictive performance of the final model,
a prediction-corrected VPC (pcVPC) was made, based on
1000 Monte-Carlo simulations. The precision of the
parameter estimates of the final model was further evalu-
ated using a non-parametric bootstrap method in which re-
sampling of the dataset was performed 1000 times to
produce new datasets with the same size but containing a
different combination of individuals and yielding new
parameter estimates and confidence intervals.
Population pharmacokinetic modelling was carried out
by non-linear mixed–effect modelling using NONMEM
version 7.2 (ICON Development solutions, Ellicott City,
MA, USA), PsN (version 4.2.0), and Xpose (version 4.5.3)
[14, 19, 20]. The Pirana interface was used for run
interpretation [21]. The first-order conditional estimation
method with interaction was used for the analysis. R
(version 3.1.10) was used for exploratory graphical anal-
ysis and for evaluation of the GOF [22].
2.4 Monte-Carlo Simulations of Different Dosing
Regimens
After selection of the final model, a simulation study was
performed using this model to assess exposure and prob-
ability of target attainment following various alternative
dosing regimens. As our ICU cohort was too small
(n = 21) for a representative weight distribution for the
population, the weight distribution from a hospital-based
cohort of 1706 adult patients from the hematology
department (2007–2014) was used to build a valid dataset
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for simulation purposes. Based on our clinical experience
and on the literature [23, 24], it was assumed that the
anthropometric characteristics in this cohort were similar to
that of a typical ICU population. The cohort consisted of
61 % men (n = 672) and had a median age (range) of
59 years (18–81), median weight (range) of 76 kg
(39–154) and median BMI (range) of 24.7 (13–42).
Five different caspofungin dosing regimens were simu-
lated: two licensed regimens and three alternative regi-
mens. These regimens were chosen at the discretion of the
researcher and based on empiric rationale. The concentra-
tion–time curves for these regimens were simulated for the
aforementioned patient cohort, without replications. The
licensed regimens included (I) a loading dose of 70 mg
followed by 50 mg maintenance in patients with
BW B80 kg or by 70 mg maintenance in patients with
BW[80 kg; and (II) 70 mg loading dose followed by
35 mg as labeled for patients with moderate or severe
hepatic dysfunction [2, 5, 6]. Alternative regimens, all
irrespective of BW, included (III) a 100 mg loading dose
followed by 50 mg maintenance; (IV) a 100 mg loading
dose followed by 70 mg maintenance; and (V) a 100 mg
loading dose followed by 100 mg maintenance.
Predicted exposure to caspofungin in terms of AUC24
was assessed on days 3 and 14 of therapy. Differences in
exposure both between treatment days within the same
regimen and between regimens on the same day of treat-
ment were statistically tested with the Wilcoxon signed
rank and Wilcoxon rank sum test, respectively.
2.5 Pharmacokinetic Target Attainment
The human clinical pharmacokinetic–pharmacodynamic
target for caspofungin in the treatment of invasive can-
didiasis has yet to be elucidated. Nevertheless, the pre-
clinical target has been determined in a neutropenic murine
model of disseminated Candida infection for which a
minimally required AUC/MIC ratio of 865 (1-log kill/24 h)
was determined for C. albicans [11]. This AUC/MIC ratio
was set as preclinical pharmacokinetic target to attain the
current study. Target attainment at day 14 following the
different dosing regimens was assessed for a wide range of
clinically relevant MIC values (0.007–1.0 lg/mL). The
mode MIC for C. albicans is 0.03 lg/mL and the epi-
demiological cut-off value is 0.12 lg/mL [25, 26].
3 Results
3.1 Patients, Dosing, and Samples
In total, 21 ICU patients treated with caspofungin were
included, yielding a total of 419 pharmacokinetic
observations. Patient characteristics and their baseline
values are summarized in Table 1. All patients were clas-
sified with Child-Pugh score B and all patients had
hypoalbuminemia (B34 g/L). Despite the fact that all
patients should have received a reduced maintenance dose
(35 mg/day) according to the label based on their Child-
Pugh score, only one of 21 patients actually received this
reduced dose. This patient received 35 mg/day for 3 of the
total 13 treatment days. In addition, four of eight patients
with BW[80 kg received a 50 mg/day maintenance dose
instead of the label-indicated 70 mg/day and two of 13
patients with BW B80 kg received a 70 mg/day mainte-
nance dose instead of the label-indicated 50 mg/day.
3.2 Population Pharmacokinetic Model
A two-compartment disposition model with first-order
elimination from the central compartment and a combined
proportional and additive residual error model fitted the
data best. The addition of a third compartment led to a
significant increase in OFV. IIV on CL, V1 and volume of
distribution of compartment 2 (V2) improved the model,
while the data did not support estimation of IIV on Q (in-
tercompartmental clearance). Allowing a correlation
between the IIV on CL and V1 further improved the model
(difference in OFV = 8.6). Parameter estimates of the final
model are shown in Table 2. CL, V1, Q, and V2 were
estimated to be 0.55, 8.93, 0.71, and 4.98. The IIV of CL,
V1, and V2 were estimated to be 30.7, 25.6, and 75.8 %
with eta shrinkage of 0, 6, and 16 %, respectively. Step-
wise covariate modelling could not identify any additional
covariates significantly affecting CL or V1. Of note, the
Child-Pugh score could not be confirmed as a covariate for
CL or V1 either.
A pcVPC of the final model is shown in Fig. 1. No
deviating trends were observed in the pcVPC, suggesting a
good predictive performance of the model to the data. This
was confirmed by the numerical predictive check, which
indicated that 1.4 % (95 % CI 0–7.9) of the observed
values lay below the 95 % prediction interval, and 4.1 %
(95 % CI 0–7.7) fell above the 95 % prediction interval.
Parameter precisions using a bootstrap re-sampling
approach of the final model are listed in Table 2. Basic
GOF plots are shown in Fig. 2. No major deviations were
detected from the plots.
3.3 Monte-Carlo Simulations of Alternative Dosing
Regimens
Alternative dose regimen simulations were performed in a
cohort of 1706 hospitalized patients. AUC24 values on
days 3 and 14 achieved by different dosing regimens are
shown in Fig. 3. Median (range) AUC24 values on day 3
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for regimens I–V were 96 (39–405), 65 (22–241), 93
(33–344), 122 (44–444), and 167 (62–594) mgh/L. Med-
ian (range) AUC24 values on day 14 for regimens I–V were
105 (39–459), 65 (22–271), 93(32–387), 130 (44–541), and
186 (64–772) mgh/L, respectively, showing that the regi-
men with a 70 mg loading dose followed by 35 mg as
labeled for patients with a Child-Pugh score of B (regimen II)
resulted in the lowest median exposure (65 mgh/L). The
Wilcoxon signed rank test confirmed significant differences
in exposure between days 3 and 14within one regimen for all
regimens (p\ 0.01). There was also a significant difference
in exposure (AUC24) between all five regimens at day 14
(p\ 0.01, Wilcoxon rank-sum).
Predicted variability in exposure was considerable, with
coefficient of variation percentages in AUC24 of 44–45 and
46–47 % for days 3 and 14, respectively, for all regimens.
Table 1 Patient demographics
of the intensive care unit cohort
used to develop the population
pharmacokinetic model
Evaluable ICU patients (n = 21)
Demographics
Female [n (%)] 8 (38)
Age (years) [median (range)] 71 (45–80)
Weight (kg) [median (range)] 75 (50–99)
BMI (kg/m2) [median (range)] 24.9 (19.0–36.4)
Clinical characteristics (at baseline)
Hepatic dysfunction, Child-Pugh B [n (%)] 21 (100)
Neutropenia [n (%)] 0 (0)
Hypoalbuminemia [n (%)]
25–34 g/L 4 (19)
15–24 g/L 14 (68)
\ 15 g/L 3 (14)
Infection location [n (%)]
Normally sterile location 16 (76)
Blood 4 (19)
Prophylaxis [n (%)] 1 (5)
BMI body mass index, ICU intensive care unit
Table 2 Pharmacokinetic parameter estimates of the final model and bootstrap analysis
Parameter Parameter estimates [RSE]
(shrinkage)
Bootstrap results parameter estimates
(n = 904)a {Mean (95 % CI) [Rel SE]}
CL (L/h)b 0.55 [7 %] 0.55 (0.46–0.62) [6.6 %]
V1 (L)
b 8.93 [8 %] 8.98 (7.90–10.43) [7.0 %]
Q (L/h)c 0.707 [3 %] 0.70 (0.46–0.92) [17.1 %]
V2 (L)
c 4.98 [17 %] 4.99 (3.50–6.94) [16.7 %]
IIV CL (CV%) 30.7 [31 %] (0 %) 29.4 (19.8–38.3) [31.0 %]
IIV V1 (CV%) 25.6 [51 %] (6 %) 25.5 (14.0–37.8) [48.7 %]
IIV Q 0 Fix 0 Fix
IIV V2 (CV%) 75.8 [65 %] (16 %) 73.4 (16.5–145) [71.7 %]
Proportional residual error 0.148 [17 %] 0.147 (0.127–0.167) [6.8 %]
Additional residual error
(mg/L)
Fix 0.01
CL clearance, CV% percentage coefficient of variation, IIV inter-individual variability, Rel SE relative standard error (100 % 9 standard
deviation/mean), RSE root square error (based on covariance step in NONMEM), V1 volume of distribution of compartment 1, V2 volume of
distribution of compartment 2, Q intercompartmental clearance
a Based on 904/1000 successfully converged runs
b CL and V1 were standardized to a body weight of 70 kg
c Q and V2 are scaled to the mean of the population
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Typical simulated plasma concentration–time profiles
with 95 % confidence intervals during 2 weeks of treatment
following the different dosing regimens are shown in Fig. 4.
As expected, a higher loading dose resulted in higher expo-
sure early in therapy (regimens III and IV vs. regimen I).
Steady state was usually reached at day 7 (168 h).
3.4 Pharmacokinetic Target Attainment
Simulated attainment of pharmacokinetic targets for the
various dose regimens is shown in Fig. 5, and Table 3
shows the probabilities of target attainment stratified by
BW.
Fig. 1 Visual predictive check
for the final pharmacokinetic
model of caspofungin, based on
n = 1000 simulations.
Prediction-corrected simulated
(shaded areas) and observed
(circles and lines) caspofungin
concentrations versus time after
dose (h). The thick red line
connects the observed median
values per bin. The solid blue
lines connect the 5th and 95th
percentiles of the observations.
The blue areas are the 95 %
confidence interval of the 5th
and 95th percentiles. The red
area indicates the confidence
interval of the median
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Fig. 2 Goodness-of-fit plots for
the final pharmacokinetic model
of caspofungin. The solid black
lines indicate the unit line or the
line of identity. The thick lines
(red or blue) are smooth lines
showing the trend in the
observations. CWRES
conditional weighted residuals
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Both licensed regimen I (based on BW) and II (reduced
based on Child-Pugh B) resulted in a pharmacokinetic
target attainment of[99 % using a MIC of 0.03 lg/mL
(mode).
Not surprisingly, the probability of target attainment
increased with increasing doses. For example, a substantial
difference in target attainment was observed between the
licensed regimen II (reduced dosing based on Child-Pugh
score B) and the alternative regimen V (100 mg load-
ing ? 100 mg/day maintenance): 14 versus 97 %, respec-
tively, for an MIC of 0.125 lg/mL. From a MIC of
0.125 lg/mL, the differences in pharmacokinetic target
attainment between the dosing regimens become more
important. Thus, for infections with species with higher
MICs, though occurring less frequently, dose will probably
have an important effect on outcome.
Higher BW consistently resulted in decreased target
attainment (Table 3), and this effect was statistically sig-
nificant (p\ 0.01). This decreased target attainment was
the direct result of a relatively decreased AUC24 for higher
BW patients. Certainly for the higher BW ranges combined
with a Child-Pugh B score, better target attainment was
observed with higher maintenance doses (regimen II vs.
III) (Table 3).
Better target attainment was observed with higher
loading and maintenance doses than suggested by the label,
as depicted in Table 3. For example, 35 mg/day mainte-
nance (regimen II) resulted in 59–81 % target attainment
and 70–100 mg/day (regimens IV and V) resulted
in[99.5 % target attainment, with an MIC of 0.06 lg/mL.
4 Discussion
This is the first study reporting a population pharmacoki-
netic model of caspofungin in ICU patients. The developed
model was successfully used to assess the probability of
pharmacokinetic target attainment for various caspofungin
dose regimens. The simulations revealed insufficient target
attainment with the currently licensed regimens. In non-
cirrhotic ICU patients classified with Child-Pugh B,
reducing the dose of caspofungin is not recommended.
Caspofungin population pharmacokinetics were com-
parable with those reported in earlier studies [18, 27]. In
contrast to other reported studies, our data did not support a
third structural peripheral pharmacokinetic compartment,
possibly due to the sparseness of the data in the late
elimination phase. The typical CL for caspofungin was
0.55 L/h and was slightly higher than reported in earlier
studies amongst other patient groups (0.40 and 0.46 L/h)
[18, 27]. Vd values were also slightly higher than in earlier
studies [18, 27]. Moderate IIV was observed for both CL
(30.7 %) and V1 (25.6 %) and also confirmed earlier lit-
erature [18, 27]. No additional covariates, including Child-
Pugh score, could be identified that significantly affected
the CL or V1 of caspofungin in the current study. On the
basis of previous results and on the well-established gen-
eral physiological mechanisms supporting the standard
allometric scaling of compound metabolism and disposi-
tion [28–30], BW was added a priori allometrically on CL
(exponent of 0.75) and V1 (exponent of 1). This approach is
widely accepted if the drug of choice distributes widely
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Fig. 3 a AUC24 on day 3 for the whole cohort, irrespective of body
weight. b AUC24 on day 14 for the whole cohort, irrespective of body
weight. The horizontal line represents the AUC24 for healthy
volunteers. Regimens: (I) loading dose of 70 mg followed by
50 mg maintenance in patients with body weight B80 kg or by
70 mg maintenance in patients with body weight[80 kg; (II) 70 mg
loading dose followed by 35 mg; (III) 100 mg loading dose followed
by 50 mg maintenance; (IV) 100 mg loading dose followed by 70 mg
maintenance; and (V) 100 mg loading dose followed by 100 mg
maintenance. AUC area under the concentration–time curve, AUC24
AUC from time zero to 24 h
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into tissues, strengthening the assumption of BW relating
to V1 [31]. Metabolism of caspofungin involves sponta-
neous degradation, hydrolysis and N-acetylation, processes
expected to be related to BW also [5, 31].
Conflicting results on covariates and caspofungin phar-
macokinetics exist in the literature. One study could not
find any covariates significantly affecting the pharma-
cokinetic parameters [27], whereas another study found a
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Fig. 4 Caspofungin concentration–time curve for a regimen I: a
loading dose of 70 mg followed by 50 mg maintenance in patients
with body weight B80 kg or by 70 mg maintenance in patients with
body weight[80 kg; b regimen II: 70 mg loading dose followed by
35 mg as labeled for patients with moderate or severe hepatic
dysfunction [2, 5, 6]; c regimen III: a 100 mg loading dose followed
by 50 mg maintenance; d regimen IV: a 100 mg loading dose
followed by 70 mg maintenance; and e regimen V: a 100 mg loading
dose followed by 100 mg maintenance. The thick black lines are
medians and the dotted lines are the 5 and 95 % percentiles. Conc
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Fig. 5 Target attainment versus
MIC for all five simulated
regimens based on a preclinical
target AUC/MIC ratio of[865.
Asterisk Indicates that the
regimen is based on body
weight: the maintenance dose
was 50 mg for patients with
body weight B80 kg and 70 mg
for body weight[80 kg. AUC
area under the concentration-
time curve, MIC minimal
inhibitory concentration
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linear relationship between BW and CL and V1 [18]. In a
study on the pharmacokinetics of caspofungin in obese
subjects, it was found that BW was allometrically related to
CL (power 0.75) for subjects weighing[66.3 kg (n = 14).
In addition, increased BW was associated with both lower
maximum (peak) concentrations (Cmax) and lower AUC
from time zero to 72 h (AUC72) values [16].
Despite our attempt to approach this by non-linearmixed–
effect modelling, no covariate could be identified on top of a
priori allometric scaling of CL and V1 by BW. In our cohort,
all ICU patients were classified as Child-Pugh B (mainly
driven by their albumin status), making it impossible to
distinguish between classes. To accurately identify the effect
of cirrhosis (using Child-Pugh classification) on caspofungin
exposure, a more heterogeneous cohort in terms of liver
function should be studied. In addition, pharmacokinetics in
ICU patients are infamously variable due to a mixture of
factors (e.g., systemic inflammatory response, capillary leak,
protein binding capacity) [32]. As such, covariates might be
obscured due the overall high variability in ICU patients and
our limited sample size.
Simulation of different dosing regimens showed that
reducing the maintenance dose to 35 mg, which is rec-
ommended for patients with moderate to severe hepatic
dysfunction (classified as Child-Pugh B or C), resulted in
the lowest average exposure. The median AUC24 was
65 mgh/L for this regimen, which is far below the
100 mgh/L typically observed for caspofungin [8, 33]. As
the Child-Pugh score is highly driven by albumin, ICU
patients with hypoalbuminemia are often unfairly classified
with Child-Pugh score B. In our cohort, all patients had an
albumin of\28 g/L, scoring them automatically with 7
points (Child-Pugh B). Decreasing the dose in ICU patients
with a Child-Pugh B score without liver cirrhosis will lead
to unnecessary low exposure, risking loss of efficacy of
caspofungin. As caspofungin is highly protein bound
(92–97 %), hypoalbuminemia might lead to changes in
caspofungin free fraction [31]. It is currently unknown
whether hypoalbuminemia can influence the pharmacoki-
netics of caspofungin.
Due to a lack of a clinically validated pharmacokinetic–
pharmacodynamic target for caspofungin, a preclinical
pharmacokinetic–pharmacodynamic target was used. It is
not the target attainment itself but rather the magnitude
change with various dosing regimens in relation to patho-
gen susceptibility that is important. Despite the use of a
preclinical target, our results are in line with reported
response rates of caspofungin in the literature, which show
that clinical and mycological cure at the end of therapy is
usually 72–73 % [2, 34]. Low exposure to caspofungin
might result in clinical failure; high exposure, on the other
hand, does not appear to lead to safety precautions:
caspofungin has an overall favorable safety profile, and
therapy with 150 mg daily is well-tolerated in patients with
invasive candidiasis [35–37]. To achieve an optimal
probability of target attainment, we recommend the use of
a caspofungin 70–100 mg maintenance dose in the setting
of an infection with pathogens with an attenuated MIC
([0.125 lg/mL). Irrespective of the susceptibility profile in
the invading pathogen, patients may benefit from a higher
loading dose of 100 mg on day 1 to achieve early adequate
exposure (see Fig. 4).
Some challenges remain for future work. First of all,
data pooling is clearly needed to achieve sufficient power
to detect relevant covariates specifically in the light of the
heterogeneous ICU population. Clearly, a more stratified
approach taking into account pathogen susceptibility
needs to be validated in terms of general mycological and
clinical cure. A study designed to identify the clinical
breakpoint for caspofungin in invasive candidiasis is
warranted. In the meantime, caspofungin dose reductions
based on Child-Pugh B scores do not appear to be valid
for non-cirrhotic ICU patients. Ultimately, therapeutic
drug monitoring, i.e., individualized drug dosing based on
the measurement and interpretation of drug concentrations
recognizing the pathogen susceptibility, could be an
important tool to derive an optimal exposure in the
individual patient.
Table 3 Preclinical target attainment
Preclinical target attainment (%)
MIC (lg/mL) 0.016 0.03 0.06 0.125 0.25 0.5 1.0
Regimen I
BW B80 kg 100 100 98 43 6 1 0
BW[80 kg 100 100 99.5 55 8 1 0
Regimen II
BW B80 kg 100 100 81 17 0.4 0
BW[80 kg 100 99.5 59 9 0.4 0
Regimen III
BW B80 kg 100 100 98 43 6 0
BW[80 kg 100 100 90 22 3 0
Regimen IV
BW B80 kg 100 100 100 78 17 0.3 0
BW[80 kg 100 100 99.5 55 9 0.4 0
Regimen V
BW B80 kg 100 100 100 97 43 6 0
BW[80 kg 100 100 100 88 22 3 0
Licensed regimens: (I) loading dose of 70 mg followed by 50 mg
maintenance in patients with BW B80 kg or by 70 mg maintenance in
patients with BW[80 kg; (II) 70 mg loading dose followed by
35 mg. Experimental regimens (all irrespective of body weight): (III)
100 mg loading dose followed by 50 mg maintenance; (IV) 100 mg
loading dose followed by 70 mg maintenance; and (V) 100 mg
loading dose followed by 100 mg maintenance
BW body weight, MIC minimal inhibitory concentration
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